Clinical features of patients with anti-myelin oligodendrocyte glycoprotein (MOG) antibody-positive optic neuritis with a certain antibody-binding epitope on human MOG extracellular domain
ECTRIMS Online Library. Tanaka K. Oct 12, 2018; 232047; 294
Keiko Tanaka
Keiko Tanaka

Abstract: 294

Type: Scientific Session

Abstract Category: Clinical aspects of MS - Neuro-ophthalmology

Background: Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies have been identified in several clinical phenotypes such as acute disseminated encephalomyelitis (ADEM) in children and seronegative neuromyelitis optica(NM0), isolated optic neuritis (ON), or myelitis together with ON in adults.This study aims to elucidate clinical features of ON with anti-MOG antibodies and their antibody-binding site on the human MOG protein.
Methods: In this study, we gathered 571 serum samples with acute ON from 33 institutions across Japan (April 2015--January 2018). All samples were obtained before the treatment initiation. Of note, serum samples and their clinical information were procured after obtaining informed consent and approval from the Medical Research Ethical Committee of each institution. In addition, we assessed anti-MOG antibodies, along with anti-aquaporin (AQP) 4 antibodies, using an in-house cell-based assay based on a previously described method (Tanaka M. et al. 2014) and evaluated the clinical characteristics of patients with anti-MOG-positive ON (MOG-ON) compared with anti-AQP4-positive ON (AQP4-ON). Next,we examined the antibody-binding epitope on the MOG protein recognized by the sera from ON using several human MOG mutants with the substitution of amino acids in the exon 2 of the extracellular domain.
Results: Of 571 serum samples, we detected AQP4-ON and MOG-ON in 12.5% and 10.2%, respectively. MOG-ON developed in both genders equally, and MOG-ON with optic disc swelling responded to immunotherapy better than those without disc swelling. Although the relapse rates between MOG-ON and AQP4-ON were similar, the result of visual acuity was better in patients with MOG-ON than in those with AQP4-ON. The antibody titers in the acute stage of MOG-ON were higher than that in MOG-myelitis, and the main antibody-binding epitopes were different between each group.
Conclusions: MOG-ON exhibits some typical clinical features such as high antibody titer with a certain antibody-binding epitope that differ from MOG-myelitis.
Disclosure: K.T. received speaker honoraria from Daiichi-Sankyo Co. M.K. has nothing to disclose, T.K. received speaker honoraria from AbbVie, Inc, Alcon Laboratories, Inc., Cosmic Corp, Eisai, Co. Ltd, Kowa, Co. Ltd, Mitsubishi Tanabe Pharma, Santen, Inc., Senju, Inc. H.I. received research grant from Kao Corp.
Funding K.T. has received research grant from JSPS KAKENHI (Grant numbers 17K11477), and K.T, T.K., H.I. have received research grant from Health and Labour Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour, and Welfare of Japan

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies